Stock data
Estrella Immunopharma, Inc. (ESLA)
Estrella Immunopharma, Inc. (ESLA) reported net income of -US$13.06M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$13.06M | -US$13.06M | — |
| 2024 | — | — | -US$7.31M | -US$7.31M | — |
| 2023 | — | — | -US$11.11M | -US$11.11M | — |
| 2022 | — | — | -US$1.57M | -US$1.00M | — |
| 2021 | — | — | -US$0.25M | -US$0.25M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$2.31M | — |
| 2026-03-31 | — | -US$2.29M | — |
| 2025-12-31 | — | -US$0.61M | — |
| 2025-09-30 | — | -US$4.80M | — |
| 2025-06-30 | — | -US$5.54M | — |
| 2025-03-31 | — | -US$2.10M | — |
| 2024-09-30 | — | -US$3.38M | — |
| 2024-06-30 | — | -US$3.95M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.